Emergent BioSolutions Selects Axiom Fusion eClinical Suite as Its Global eClinical Suite
04 Março 2020 - 11:00AM
Axiom Real-Time Metrics (“Axiom”), premier provider of unified
eClinical solutions and services is pleased to announce its
engagement with Emergent BioSolutions (NYSE: EBS), a global life
sciences company whose mission is to protect and enhance life by
providing specialty products and contract development and
manufacturing services that address public health threats.
Andrew Schachter, Founder & CEO of Axiom, shared, “Axiom is
passionate about giving sponsors solutions that harness the power
of their data to drive clinical research. We deliver technology and
services to innovative life sciences organizations to provide them
with the information that they need – in real-time – so that they
are empowered with the robust and timely insights which are
required for compliance, effective trial conduct, and successful
drug development. We are very pleased to build this relationship
with Emergent and potentially be a long-term partner in meeting
their evolving needs as they develop drugs that are critical to
patient well-being and position them at the leading edge of
infectious disease treatments.” Paul-André de Lame, VP, Clinical
Development at Emergent stated, “We are delighted to have found a
fully integrated clinical suite that will allow us to scale up
seamlessly while optimizing our processes to capitalize on the
unmatched potential offered by Axiom’s Fusion platform.”
Meredith Frank-Molnia, Senior Director Clinical Management at
Axiom, expressed, “We are integral partners to our sponsors,
driving clinical development success through the unique combination
of thoughtful planning, best-in-class Fusion eClinical technology,
and our Axiom team members who are passionately dedicated to their
trials.”
“Emergent has a distinctive position in the life sciences space
with its focus on infectious disease and endemic illness. Their
choice of Axiom’s unified technology platform to deploy end-to-end
solutions quickly is a major source of pride for us and validates
our mission,” further contributed Kaitlyn Townsley, Associate
Director of Product Innovation at Axiom.
“We fully appreciate the importance and the trust that our
clients place in us. Emergent is engaging us to empower their
studies, which we know may affect generations to come. We look
forward to a long-term strategic relationship with such an
innovative and leading-edge client; one poised to have such
significant impact to the health and well-being of so many,”
concluded Andrew Schachter. About Axiom Real-Time
Metrics Headquartered in Toronto, Canada, Axiom delivers
intuitive, powerful and cost-effective eClinical solutions and
services focused around your entire study. Services include: Data
Management, Data Analytics, Biostatistics and Pharmacovigilance.
Axiom's eClinical suite, Fusion, delivers a powerful range of
innovative end-user focused, unified functionality and 15 modules.
Axiom serves as the Connected Hub for your entire clinical study
data and operational needs. Fusion Delivers: EDC, DM, IWRS, CTMS,
Inventory Management, IVR, Patient Portal, AE/SAE Tracking, Safety
Database, Central Lab, Imaging, eTMF, and 24/7 Project and Clinical
Data Reporting. For more information, please visit
http://www.axiommetrics.com/.
Contact solutions@axiom.cc +1.877.321.9191
PR Contact Sarah Glofcheskie
sarahg@axiom.cc +1.647.588.9073
Emergent Biosolutions (NYSE:EBS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Emergent Biosolutions (NYSE:EBS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024